ESE-1 is required to maintain the transformed phenotype of MCF-7 and ZR-75-1 human breast cancer cells

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 77-88

  Walker, Darius M ^a   Poczobutt, Joanna M ^a   Gonzales, Melissa S ^a   Horita, Henrick ^a   Gutierrez Hartmann, Arthur ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Ets; Shrna; Transformation

Indexed keywords

EPITHELIAL SPECIFIC ETS FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; COLONY FORMATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 78249289121     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010077     Document Type: Article

References (44)

1. Gutierrez-Hartmann A, Duval DL, Bradford AP. ETS transcription factors in endocrine systems. Trends Endocrinol Metab 2007; 18: 150-158.
2. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303: 11-34.
3. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-837.
4. Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras/MAP kinase signaling pathway. Trends Biochem Sci 1998; 23: 213-216.
5. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478.
6. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-6448.
7. Andreoli J, Jang S-I, Chung E, Coticchia C, Steinert P, Markova N. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res 1997; 25: 4287-4295.
8. Feldman RJ, Sementchenko VI, Watson DK. The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res 2003; 23: 2125-2131.
9. Oettgen P, Alani R, Barcinski M, et al. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol 1997; 17: 4419-4433.
10. Tymms M, Ng A, Thomas R, et al. A novel epithelial-expressed ETS gene, ELF3: Human and murine cDNA sequences, murine genomic organization, human mapping to 1q.32.2 and expression in tissues and cancer. Oncogene 1997; 15: 2449-2462.
11. Neve R, Chang C-H, Scott G, et al. The epithelium-specific Ets transcription factor ESX is associated with mammary gland development and involution. FASEB J 1998; 12: 1541-1550.
12. Chang CH, Scott GK, Kuo WL, et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997; 14: 1617-1622.
13. Neve RM, Ylstra B, Chang CH, Albertson DG, Benz CC. ErbB2 activation of ESX gene expression. Oncogene 2002; 21: 3934-3938.
14. Benz C, O'Hagan R, Richter B, et al. HER2/Neu and the Ets transcription activator PEA3 are coordinatley upregulated in human breast cancer. Oncogene 1997; 15: 1513-1525.
15. Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE, Gutierrez-Hartmann A. The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol 2003; 22: 79-94.
16. O'Hagan R, Hassell JA. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 1998; 16: 301-310.
17. Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 2004; 279: 11281-11292.
18. Delannoy-Courdent A, Mattot V, Fafeur V, et al. The expression of Ets-1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci 1998; 111: 1521-1534.
19. Sapi E, Flick M, Rodov S, Kacinski B. Ets-2 transdominant mutant abolishes anchorage-independent growth and macropahge-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res 1998; 58: 1027-1933.
20. Prescott J, Koto K, Singh M, Gutierrez-Hartmann A. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol 2004; 24: 5548-5564.
21. Schedin P, Eckel-Mahan K, McDaniel S, et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 2004; 23: 1766-1779.
22. Witt AE, Hines LM, Collins NL, et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 2006; 5: 599-610.
23. Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004; 89: 272-280.
24. Chang C, Scott G, Kuo W, et al. ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997; 14: 1617-1622.
25. Choi S-G, Yi Y, Kim Y-S, et al. A novel Ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-ß type II receptor. J Biol Chem 1998; 273: 110-117.
26. Kim JH, Wilder PJ, Hou J, Nowling T, Rizzino A. Activation of the murine type II transforming growth factor-beta receptor gene: up-regulation and function of the transcription factor Elf-3/Ert/Esx/Ese-1. J Biol Chem 2002; 277: 17520-17530.
27. Park SH, Kim YS, Park BK, Hougaard S, Kim SJ. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression. Oncogene 2001; 20: 1235-1245.
28. Manavathi B, Rayala SK, Kumar R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. J Biol Chem 2007; 282: 19820-19830.
29. Chang C-H, Scott GK, Baldwin NA, Benz CC. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene 1999; 18: 3682-3695.
30. He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 2007; 6: 76-82.
31. Paine TM, Soule HD, Pauley RJ, Dawson PJ. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer 1992; 50(3): 463-473.
32. Do HJ, Song H, Yang HM, et al. Identification of multiple nuclear localization signals in murine Elf3, an ETS transcription factor. FEBS Lett 2006; 580: 1865-1871.
33. Choi Y, Asada S, Uesugi M. Divergent hTAFII31-binding motifs hidden in activation domains. J Biol Chem 2000; 275: 15912-1596.
34. Wang H, Fang R, Cho JY, Libermann TA, Oettgen P. Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86. J Biol Chem 2004; 279: 25241-25250.
35. Asada S, Choi Y, Yamada M, et al. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci USA 2002; 99: 12747-12752.
36. Brown C, Gaspar J, Pettit A, et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 2004; 279: 12794-12803.
37. Grall F, Gu X, Tan L, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003; 48: 1249-1260.
38. Jobling AI, Fang Z, Koleski D, Tymms MJ. Expression of the ETS transcription factor ELF3 in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2002; 43: 3530-3537.
39. Barrett JM, Puglia MA, Singh G, Tozer RG. Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. Breast Cancer Res Treat 2002; 72: 227-232.
40. Lindemann RK, Braig M, Hauser CA, Nordheim A, Dittmer J. Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. Biochem J 2003; 372: 787-797.
41. Neznanov N, Man A, Yamamoto H, Hauser C, Cardiff R, Oshima R. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 1999; 59: 4242-4246.
42. Man AK, Young LJ, Tynan JA, et al. Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol 2003; 23: 8614-8625.
43. Scott GK, Chang CH, Erny KM, et al. Ets regulation of the erbB2 promoter. Oncogene 2000; 19: 6490-6502.
44. Chiang SY, Burli RW, Benz CC, et al. Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J Biol Chem 2000; 275: 24246-24254.